Success Story

Neuralert’s first product receives FDA Breakthrough Designation

Neuralert Technologies, a startup spun out of Penn Medicine and Penn Engineering that was co-founded by Steven Messé, MD, Penn Medicine Physician and Professor of Neurology  and James Weimer, PhD, Assistant Professor in the Department of Computer Science at Vanderbilt University (previously at Penn), is developing technologies and products to help address the problem of late or undetected stroke in hospitalized patients. The Penn co-founders created technology that uses non-invasive, wearable devices to continuously monitor at-risk hospitalized patients for stroke symptoms and, in the event of a potential stroke, automatically alert clinical staff resulting in more rapid assessment and treatment of the patient. The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has designated the lead Neuralert  product candidate as a Breakthrough Device, further accelerating its clinical development as a device to “detect the onset of asymmetric movement in hospitalized patients with medical conditions or procedures that are established risks for stroke and who have no baseline asymmetric upper extremity weakness.”

Skip to content